A new perspective article （Levkina, Vermonden et al.）argues that answering five fundamental questions about ferroptosis, an iron-dependent form of cell death, could define the direction of research in the coming decade.
Published in the open-access journal Ferroptosis and Oxidative Stress , the article outlines key conceptual challenges that remain unresolved despite the field’s rapid expansion over the past ten years.
Ferroptosis is a regulated cell death caused by iron-dependent lipid peroxidation in membranes. Unlike apoptosis or necrosis, it results from failure of defenses like glutathione peroxidase 4 (GPX4), ferroptosis suppressor protein-1 (FSP1), and vitamin E, which protect polyunsaturated lipids in phospholipids. When these defenses fail, lipid peroxidation spreads, rupturing the cell. In recent years, ferroptosis has gained attention due to its role in diseases such as cancer, neurodegeneration, and ischemia-reperfusion injury, but its biology is still not fully understood.
In the article, the authors frame the future of ferroptosis research around five unresolved riddles:
1. Why does ferroptosis exist? If it's harmful, what purpose does it serve? The authors trace its molecular roots to over 3.8 billion years ago, suggesting that vulnerability to iron-catalyzed lipid peroxidation is an ancient relic. Proteins like GPX4 and FSP1 are conserved across species, indicating that suppressing ferroptosis has been a key evolutionary focus.
2. What exactly is the role of iron? Iron is clearly essential for ferroptosis, but its precise biochemical and physiological contributions remain debated. Whether it acts primarily through free-radical chemistry in the labile iron pool, through iron-bound enzymes such as lipoxygenases, or at specific organelles, recent work implicates lysosomes as an early site of peroxidation, but this remains unresolved.
3. Where is ferroptosis initiated? Researchers still do not fully understand which cellular compartments or tissues trigger ferroptotic processes in living organisms. Proposed initiation sites include the endoplasmic reticulum, mitochondria, ER–mitochondrial contact sites, and lysosomes, each supported by distinct experimental evidence. The answer is likely context-dependent, shaped by the local abundance of iron, the phospholipid composition of organelle membranes, and the status of nearby antioxidant defenses.
4. Can ferroptosis be safely targeted for therapy? While drugs that induce or inhibit ferroptosis show promise in experimental models, translating these strategies into clinical treatments remains challenging.
5. Is ferroptosis truly a regulated form of cell death? Unlike apoptosis, driven by caspases, or necroptosis, requiring kinase activation, ferroptosis needs no trigger; it is continuously suppressed. Some see it as the biochemical result of uncontrolled phospholipid oxidation rather than a programmed pathway. Ferroptosis might lack a single 'point of no return” and operate via a peroxidation threshold: when lipid damage surpasses repair capacity, membrane fails. Feedback mechanisms like ESCRT-III and NRF2 may delay, but not always prevent, this outcome.
The authors argue that future ferroptosis research should focus less on discovering new molecules and more on understanding the process's broader conceptual and biological roles. They highlight an emerging aspect: intercellular dialogue, where dying ferroptotic cells release signals that influence immune responses variably, often impacting cancer immunotherapy.
Resolving these riddles could clarify how ferroptosis contributes to disease and whether manipulating the pathway could become a viable therapeutic strategy.
People
The coming decade in ferroptosis research: Five riddles
6-Jan-2026